COVID-19 and molecular hydrogen inhalation

PMID: 32865158 PMCID: PMC7459175 DOI: 10.1177/1753466620951051

Sergej M. Ostojic Author information Copyright and License information Disclaimer

Recent public reports by China’s National Health Commission and the Chinese Center for Disease Control and Prevention have recommended effective oxygen therapy measures as an element of general treatment in patients with novel coronavirus pneumonia (COVID-19).1,2 Both documents disclosed a rather exotic ratio of hydrogen and oxygen (66.6% H2 to 33.3% O2) as the composition of the gas mixture for inhalation. While high oxygen levels are administered due to apparent lung dysfunction in COVID-19, blending with hydrogen gas for a breathing mixture remains puzzling. Hydrogen is most likely added as an inert part of the breathing gas but it may have beneficial effects by itself.

A recent study suggested that hydrogen gas inhibits airway inflammation in patients with asthma,3 an effect that might improve the condition of inflammatory cytokines storm seen in COVID-19.4 Two multicenter randomized controlled trials (RCTs) with inhalational hydrogen for COVID-19 are listed in the World Health Organization (WHO) clinical trials registry in February and March 2020 yet no evidence to back up this approach is available as yet. Another factor must also be taken into consideration: the potential of high-concentration hydrogen to cause explosion ignited by static electricity.

Like other promising (and urgently needed) therapeutics for COVID-19, gaseous hydrogen thus requires accelerated yet attentive research and approval pathways, with sufficient efficacy and safety guarantees.5Cutting off the corners for the simplest molecule in the Universe may be a step back for the hydrogen research community beyond this particular coronavirus.Go to:

Footnotes

Contributed by 

Author contribution(s): Sergej M. Ostojic: Conceptualization; Data curation; Formal analysis; Investigation; Project administration; Supervision; Validation; Writing-original draft; Writing-review & editing.

Conflict of interest statement: The author declares that there is no conflict of interest.

Funding: The author received no financial support for the research, authorship, and/or publication of this article.

ORCID iD: Sergej M. Ostojic An external file that holds a picture, illustration, etc.
Object name is 10.1177_1753466620951051-img1.jpg https://orcid.org/0000-0002-7270-2541Go to:

References

1. National Health Commission of the People’s Republic of China. New coronavirus pneumonia diagnosis and treatment guideline. 7th trial ed NHC: Bejing, 2020. [Google Scholar]

2. Chinese Center for Disease Control and Prevention. Protocol for prevention and control of COVID-19. 6th ed. CDCP: Bejing, 2020. [Google Scholar]

3. Niu Y, Nie Q, Dong L, et al. Hydrogen attenuates allergic inflammation by reversing energy metabolic pathway switch. Sci Rep 2020; 10: 1962. [PMC free article] [PubMed] [Google Scholar]

4. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033–1034. [PMC free article] [PubMed] [Google Scholar]

5. Jiang S. Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. Nature2020; 579: 321. [PubMed] [Google Scholar]


Articles from Therapeutic Advances in Respiratory Disease are provided here courtesy of SAGE Publications

Leave a Reply

Your email address will not be published. Required fields are marked *